Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 18/20 | 0.61 |
| ▸ | GCKR | Q14397 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596636 | 1.00 | HSD11B1 (0.61) | HSD11B1GCKRCYP3A4KCNH2 | |
| SCHEMBL3605437 | 1.00 | HSD11B1 (0.61) | HSD11B1GCKRCYP3A4KCNH2 | |
| SCHEMBL13072736 | 1.00 | HSD11B1 (0.61) | HSD11B1GCKRCYP3A4KCNH2 | |
| SCHEMBL3596632 | 1.00 | HSD11B1 (0.61) | HSD11B1GCKRCYP3A4KCNH2 | |
| SCHEMBL13072515 | 0.92 | HSD11B1 (0.61) | HSD11B1GCKRCYP3A4KCNH2 | |
| SCHEMBL3608417 | 0.92 | HSD11B1 (0.61) | HSD11B1GCKRCYP3A4KCNH2 | |
| SCHEMBL3608414 | 0.92 | HSD11B1 (0.61) | HSD11B1GCKRCYP3A4KCNH2 | |
| SCHEMBL3611474 | 0.92 | HSD11B1 (0.61) | HSD11B1GCKRCYP3A4KCNH2 | |
| SCHEMBL3613804 | 0.92 | HSD11B1 (0.61) | HSD11B1GCKRCYP3A4KCNH2 | |
| SCHEMBL12576693 | 0.90 | HSD11B1 (0.59) | HSD11B1GCKRCYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825122-B2 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. (US) | 2010-11-02 | — | — | US | claimed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | claimed |
| US-7825122-B2 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825122-B2 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| WO-2007070506-A2 | DIAZA HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | GLP1R, GPR119, INSR | HSD11B1 685/4885GCKR 160/4885CYP3A4 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.